G+FLAS is applying CRISPR technology to the development of drugs and production of CRISPR genome edited plants in a non-GMO way. These products include plant-based trastuzumab, a biosimilar antibody, and a cas9 monoclonal antibody to be used to test the development of Cas9-based gene therapy products.

ERS Genomics holds the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier.

Researchers use modified CRISPR tool to manipulate the epigenome
Bioengineers have developed a new way to engineer the human epigenome (chemical changes in the DNA) using a modified CRISPR-Cas9 system to target and...

Not all genome editing tools are equal: CRISPR vs. TALEN
In recent years, a number of novel genome editing tools have emerged, although not all of these tools are equal in terms of efficiency and accuracy, according...

Tackling the next hurdle in cell and gene therapy: Manufacturing
Although innovation continues to occur at lightning fast speeds in the cell and gene therapy space, commercialization and manufacturing of these technologies...

Sherlock discovers novel CRISPR-associated enzymes
Sherlock Biosciences has announced the discovery of novel thermostable CRISPR-associated enzymes.

Vivlion licenses CRISPR tech from ERS Genomics
Vivlion has signed a nonexclusive license agreement to access ERS Genomics' CRISPR/Cas9 patent portfolio to enhance Vivlion's gene editing reagents and...